Compare BFS & SPRY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BFS | SPRY |
|---|---|---|
| Founded | 1993 | 2015 |
| Country | United States | United States |
| Employees | 98 | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 809.1M | 833.1M |
| IPO Year | N/A | 2020 |
| Metric | BFS | SPRY |
|---|---|---|
| Price | $33.67 | $8.27 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 1 |
| Target Price | ★ $44.00 | $40.00 |
| AVG Volume (30 Days) | 38.0K | ★ 1.5M |
| Earning Date | 05-07-2026 | 05-13-2026 |
| Dividend Yield | ★ 6.99% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $84,278,000.00 |
| Revenue This Year | $6.07 | $90.76 |
| Revenue Next Year | $7.05 | $81.70 |
| P/E Ratio | $30.48 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $29.16 | $6.66 |
| 52 Week High | $35.45 | $18.63 |
| Indicator | BFS | SPRY |
|---|---|---|
| Relative Strength Index (RSI) | 58.07 | 46.35 |
| Support Level | $32.42 | $8.05 |
| Resistance Level | $35.32 | $8.70 |
| Average True Range (ATR) | 0.70 | 0.54 |
| MACD | 0.14 | 0.07 |
| Stochastic Oscillator | 78.43 | 68.46 |
Saul Centers Inc is a self-managed real estate investment trust which invests in, operates and develops retail and commercial properties. The company's portfolio includes community and neighbourhood shopping centres, office properties, and mixed-use properties. Properties are located in the Washington, D.C. and Batlimore metropolitan areas. Saul Centers operates through two business segments: Shopping Centers segment, which contribute the maximum portion of total revenue; and mixed-use properties.Mixed-Use Properties segment include office, retail and multi-family residential use.
ARS Pharmaceuticals Inc is a biopharmaceutical company focused on the commercialization and development of neffy (currently identified in the European Union (EU) and United Kingdom (U.K.) by the trade name EURneffy and in China) for needle-free intranasal delivery of epinephrine for emergency treatment of Type I allergic reactions, including anaphylaxis. Neffy is a proprietary composition of epinephrine with an absorption enhancer called Intravail, which allows Neffy to safely provide intranasal delivery of epinephrine at a low dose within the exposures of approved injectable products across a range of dosing conditions.